ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Acrivon Therapeutics Inc

Acrivon Therapeutics Inc (ACRV)

7.465
0.135
(1.84%)
Closed July 23 4:00PM
7.55
-0.005
(-0.07%)
After Hours: 5:00PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
7.465
Bid
7.41
Ask
7.50
Volume
37,969
7.24 Day's Range 7.51
3.19 52 Week Range 13.20
Market Cap
Previous Close
7.33
Open
7.30
Last Trade
10
@
7.77
Last Trade Time
Financial Volume
$ 279,928
VWAP
7.3725
Average Volume (3m)
121,802
Shares Outstanding
30,876,932
Dividend Yield
-
PE Ratio
-3.81
Earnings Per Share (EPS)
-1.96
Revenue
-
Net Profit
-60.39M

About Acrivon Therapeutics Inc

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Pr... Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
1970
Acrivon Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACRV. The last closing price for Acrivon Therapeutics was $7.33. Over the last year, Acrivon Therapeutics shares have traded in a share price range of $ 3.19 to $ 13.20.

Acrivon Therapeutics currently has 30,876,932 shares outstanding. The market capitalization of Acrivon Therapeutics is $226.33 million. Acrivon Therapeutics has a price to earnings ratio (PE ratio) of -3.81.

ACRV Latest News

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) --  Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0550.7422402159247.4187.21670897.6020282CS
40.78511.7514970066.6885.641061926.74592931CS
12-0.755-9.184914841858.2210.295.641218027.64779707CS
263.11571.60919540234.3511.93.194425679.0198135CS
52-5.305-41.542678151912.7713.23.192331758.86045099CS
156-6.425-46.25629949613.8925.473.191583699.81381321CS
260-6.425-46.25629949613.8925.473.191583699.81381321CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.15M
CMAXCareMax Inc
$ 5.19
(228.48%)
102.64M
NUKKNukkleus Inc
$ 0.499
(55.94%)
26.2M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.88M
ONDSOndas Holdings Inc
$ 1.1297
(34.06%)
2.19M
CGBSCrown LNG Holdings Ltd
$ 0.9902
(-29.77%)
3.29M
LGCBLinkage Global Inc
$ 3.7833
(-27.45%)
166.7k
SPECSpectaire Holdings Inc
$ 0.395
(-24.76%)
1.78M
GSUNGolden Sun Health Technology Group Ltd
$ 5.07
(-24.55%)
155.37k
SLNASelina Hospitality PLC
$ 0.0364
(-23.04%)
75.77M
NVDANVIDIA Corporation
$ 123.45
(4.68%)
221.22M
SQQQProShares UltraPro Short QQQ
$ 8.08
(-4.49%)
176.65M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
151.42M
SERVServe Robotics Inc
$ 8.7192
(15.49%)
148.59M
NCPLNetcapital Inc
$ 0.1105
(6.25%)
121.97M

ACRV Discussion

View Posts
tw0122 tw0122 3 months ago
“Today we present initial clinical data from our ongoing Phase 2 clinical trial which we believe highlights the power of our next generation proteomics-based AP3 precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. “For the first time, we share statistically significant prospective validation of our AP3 patient selection approach via our ACR-368 OncoSignature assay, which demonstrated the ability to effectively identify cancer patients whose tumors are likely to respond to ACR-368 monotherapy treatment. We are extremely gratified to not only confirm the ability to identify and enrich for patient responders with ovarian cancer, but also for patients with endometrial cancer, a new tumor type identified and predicted to be sensitive to ACR-368 by our AP3 platform prior to clinical trial initiation.”

“Today’s R&D event provides us an opportunity to present the compelling preclinical data of our AP3-based, rationally-designed ACR-2316 dual WEE1/PKMYT1 inhibitor,” said Kristina Masson, Ph.D., M.B.A., co-founder and executive vice president of business operations at Acrivon Therapeutics, Inc. and president and CEO of the company´s research subsidiary Acrivon AB. “We are excited to announce our accelerated timelines for IND filing, now expected in the third quarter with potential clinical study initiation now anticipated in the fourth quarter of this year. We believe this potential first-in-class asset, which is specifically designed for superior single-agent activity as demonstrated in preclinical studies against benchmark inhibitors, has the potential to address significant unmet treatment needs against a broad range of tumors in patients with limited treatment options.”

Company Provides Program and Data Highlights:

An overview of the broad, actionable scientific capabilities and clinically demonstrated deliverables of the AP3 platform
Initial ACR-368 clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) in the ongoing registrational-intent Phase 2b trial are being presented (data cut as of April 1, 2024).
A confirmed ORR (per RECIST 1.1) of 50% was observed in the prospective cohort of OncoSignature-positive patients who were efficacy-evaluable. All confirmed responders continue to be on treatment, median duration of response (DoR) has not yet been reached. Notably, endometrial cancer is a new tumor type with significant unmet medical need that was identified and predicted to be sensitive to ACR-368 by AP3 indication screening.
Initial, prospective validation of the AP3-based ACR-368 OncoSignature assay demonstrating its ability to identify ovarian and endometrial patients sensitive to ACR-368 monotherapy in the ongoing clinical trial, with clear segregation of RECIST responders in the OncoSignature-positive (50% confirmed ORR in 10 patients) versus OncoSignature-negative (0% ORR in 16 patients) arms (p-value=0.0038).
In the OncoSignature-negative arm with ovarian or endometrial cancers, encouraging signs of clinical activity were observed in response to ACR-368 with ultra-low dose gemcitabine at the recommended Phase 2 combination dose, with 8 out of 16 patients achieving stable disease.
Consistent with past trials, the ACR-368 treatment-related adverse event profile was predominantly reversible and transient with only mechanism-based, hematological adverse events.
ACR-2316, a potential first-in-class, potent WEE1/PKMYT1 inhibitor continues to advance rapidly with IND filing now expected in Q3 2024 (vs. previous guidance of Q4 2024) and the initiation of a clinical trial is anticipated in Q4 2024. ACR-2316 is uniquely designed by AP3 for superior single-agent activity and to overcome limitations of current WEE1 inhibitors and PKMYT1 inhibitors.
A preview of the AP3 Interactome, which is a proprietary, machine-learning-enabled interactive platform used to uncover actionable drug-induced pathway effects across all studies.
A live and recorded webcast of the event will be available through a link on the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations. The webcast will be available for at least 30 days following the event.
👍️0
Monksdream Monksdream 3 months ago
ACRV update
👍️0
Monksdream Monksdream 3 months ago
Nope do your research
👍️0
PonkenPlonken PonkenPlonken 3 months ago
TY. is that always the read on your xxx under xx posts?
👍️0
Monksdream Monksdream 3 months ago
Still a buy
👍️0
PonkenPlonken PonkenPlonken 3 months ago
please elaborate on "ACRV under 10" = Its a buy under 10? TIA
vice versa xxx over xxx = short?
👍️0
Monksdream Monksdream 3 months ago
One day wonder
👍️0
Awl416 Awl416 3 months ago
Acrivon Therapeutics Announces $130 Million Private Placement Financing
👍️0
Monksdream Monksdream 4 months ago
ACRV under $10
👍️0

Your Recent History

Delayed Upgrade Clock